ARCHIVES

Phase III Trial of ThermoDox Fails to Meet Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 2 | February 22, 2013

Download PDF Visit The Full Archive

Related Articles

LDK378 Demonstrates 58 Percent Overall Response Rate in Phase I

April 25, 2014

HHS System Of Misconduct investigation Not Suited For Clinical Trials, Broder Says

November 11, 1994

Center Program Move Definite; DCBD to Be Renamed

September 22, 1989

Durant Suggests Six Efforts Needed For Survival Of Clinical Research

May 30, 1986

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

December 16, 2011

NCAB Criticizes Coverage’ Of NCI Screening Statement

March 4, 1994